Cytochrome P450 content in primary tumors and liver metastases of patients with metastatic colorectal cancer
Keywords:colorectal cancer., cytochrome P450, liver metastases, metalloproteinase, survival
Summary. Aim: To determine the content of low-spin form of cytochrome P450 in primary tumors and liver metastases of the patients with metastatic colorectal cancer (mCRC) and and assess its prognostic significance. Materials and Methods: The levels of the oxidized and low-spin forms of cytochrome P450 in the tissues of patients with mCRC were studied by electron paramagnetic resonance. To detect CYP 1A2 and CYP 1B1 isoforms, Western blot analysis was used. The activity of metalloprotreinases was studied by gelatine zymography. Results: In the liver metastases and tissues adjacent to metastasis, the levels of low-spin forms of cytochrome P450 are lower than in the samples of conventionally normal liver tissue. Western blot analysis revealed that low-spin form of cytochrome P450 in primary tumors and liver metastases detected by electron paramagnetic resonance is attributed largely to CYP 1B1 isoform. The content of low-spin form of cytochrome P450 inversely correlated with the the activity of gelatinases (matrix metalloproteinase-2 and -9). The survival of patients with high levels of the low-spin form of cytochrome P450 in tumor tissues was higher than that of patients with low levels of the enzyme (105 months vs 61 months). Conclusion: In the primary tumors and liver metastases of patients with mCRC, the content of the low-spin form of cytochrome P450 decreased, which correlated inversely with patient’s survival.
Zarour LR. Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol 2017; 3: 163–73.
Omura T. Forty years of cytochrome P450. Biochem Biophys Res Commun 1999; 266: 690–8.
Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000; 21: 40–54.
Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000; 27: 95–112.
Hukkanen J, Pelkonen O, Hakkola J, Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 2002; 32: 391–411.
Shimada T, Gillam EM, Sutter TR, et al. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos 1997; 25: 617–22.
Chun YJ, Kim D. Cancer activation and polymorphisms of human cytochrome P450 1B1. Toxicol Res 2016; 32: 89–93.
McFadyen MC, McLeod HL, Jackson FC, et al. Cytochrome P450 CYP 1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 2001; 62: 207–12.
Jiang J-G, Ning Y-G, Chen C, et al. Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 2007; 67: 6665–74.
Burlaka AP, Burlaka АА, Virko SV, Ganusevich ІІ. Molecular mechanisms of oxidation damage and liver cell dysfunction in patients with metastatic colorectal cancer. Exp Oncol 2019; 41: 1–7.
How to Cite
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.